Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Oct 8 · inside the Ichimoku cloud · RSI 84 (overbought) · MACD above its signal
| 0.001000 | 52-week high | +614.29% |
| 0.000140 | R3 (classic) | +0.00% |
| 0.000140 | R2 (classic) | +0.00% |
| 0.000140 | R1 (classic) | +0.00% |
| 0.000140 | Pivot | +0.00% |
| 0.000140 | S1 (classic) | +0.00% |
| 0.000140 | S2 (classic) | +0.00% |
| 0.000140 | S3 (classic) | +0.00% |
| 0.000140 | Previous day high | +0.00% |
| 0.000140 | Previous day low | +0.00% |
| 0.000140 | Previous week high | +0.00% |
| 0.000140 | Previous week low | +0.00% |
| 0.000140 | Price now | |
| 0.000100 | Previous month high | −28.57% |
| 0.000100 | Previous month low | −28.57% |
| 0.000000 | 52-week low | −100.00% |
None of the 29 investors followed here reported a position in ANTH in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ANTH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ANTH.
TimeframesUp on the hourly and daily, down on the weekly, mixed on the monthly.
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 900.0 | -90.0 | 0.0 | 0.0 | 40.0 | +40.0% | ||
| 2025 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −50.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | +100.0% |
| 2023 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2022 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | -95.0 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | +0.0% |
| 2021 | 72.6 | 187.3 | -34.5 | -0.6 | 1.9 | -17.3 | -40.5 | -22.9 | -97.3 | -87.5 | 100.0 | -50.0 | −99.6% |
| 2020 | 11.9 | -21.7 | 7.0 | -26.3 | 14.4 | -2.2 | 28.8 | -3.5 | -27.6 | -17.7 | -10.5 | 37.1 | −29.7% |
| 2019 | 169.2 | 21.4 | 16.5 | -11.1 | -33.6 | 16.2 | -28.7 | -2.9 | 6.4 | -8.0 | -6.5 | -20.6 | +31.3% |
| 2018 | 1.8 | 28.0 | -85.1 | 0.2 | -26.2 | -66.5 | 7.6 | -8.8 | -3.2 | -5.5 | -50.7 | -25.7 | −98.4% |
| 2017 | -16.5 | 25.4 | -37.4 | -22.4 | -39.0 | 0.6 | -15.4 | 16.8 | -10.0 | 12.5 | 21.6 | -16.2 | −68.2% |
| 2016 | -30.4 | -6.2 | 19.5 | 2.2 | -0.5 | -16.0 | -0.3 | -6.5 | 9.4 | -30.2 | -31.8 | -56.7 | −86.0% |
| 2015 | 58.2 | 102.0 | -11.5 | -4.0 | 30.1 | 54.5 | 26.6 | -37.4 | -10.8 | -5.3 | -1.4 | -18.5 | +193.7% |
| 2014 | -4.6 | 1.0 | 13.2 | -15.5 | 9.2 | 9.7 | -14.5 | -12.4 | -24.4 | -3.1 | 10.2 | -22.9 | −48.5% |
| 2013 | 5.0 | -6.3 | 8.2 | -16.7 | 6.3 | -20.8 | 16.1 | -23.3 | 21.8 | -21.4 | -0.6 | -2.2 | −38.1% |
| 2012 | 28.7 | -16.2 | -66.6 | -29.4 | 26.3 | -65.7 | 58.2 | -15.9 | 10.4 | -10.4 | -28.2 | -3.1 | −89.9% |
| 2011 | -20.5 | 40.2 | 24.1 | 7.9 | 11.7 | 0.5 | -2.4 | -29.6 | -15.0 | 33.1 | -8.3 | 5.5 | +25.8% |
| 2010 | 1.1 | -15.8 | -9.9 | 0.4 | -29.4 | 10.3 | 49.6 | -12.8 | -10.8 | −30.2% |
No analyst coverage for this instrument.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
No recent headlines.